Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical

Facilitating Novel Health-Tech and Bio-Medical Innovations For Over 9 Million Veterans — Dr. Rachel Ramoni, Chief of R&D, U.S. Department of Veterans Affairs.

Dr. Rachel Ramoni, is the Chief Research and Development Officer of the United States Department of Veterans Affairs (VA), where she oversees their nationwide research enterprise, encompassing some 2000 active projects, at more than 100 sites, with a total budget of $2 billion in both direct VA support, and research funding from outside entities such as the National Institutes of Health, other federal agencies, and nonprofit and private organizations.

The United States Department of Veterans Affairs (VA) is a federal Cabinet-level agency that provides comprehensive healthcare services to military veterans at over 1000 VA medical centers and outpatient clinics located throughout the US – It also provides several non-healthcare benefits including disability compensation, vocational rehabilitation, education assistance, home loans, and life insurance; and provides burial and memorial benefits to eligible veterans and family members.

The VA serves over 9 million enrolled Veterans each year, employs over 377000 people with an annual budget of $200 billion.

Dr. Ramoni earned a Doctor of Medicine in Dentistry degree from the Harvard School of Dental Medicine, as well as a Master of Science and Doctor of Science in epidemiology from the Harvard School of Public Health.

Dr. Ramoni was previously on the faculty at New York University College of Dentistry in the department of epidemiology and health promotion, and at Harvard Medical School in the department of biomedical informatics.

While at Harvard, Dr. Ramoni founded and led the Undiagnosed Diseases Network (UDN) Coordinating Center, which was funded by the National Institutes of Health, and brings together clinical and research experts from across the U.S. to solve challenging medical mysteries using advanced technologies.

Among Dr. Ramoni’s research interests are informatics, genomics, and precision medicine. Prior to her role with the UDN, she was executive director of the Substitutable Medical Applications, Reusable Technologies project, or SMART. Initially launched with federal funding, SMART aims to make it easier for providers across different health systems to securely share information from electronic health records. The overarching goal is to improve the quality and continuity of care for patients.

Read more | >

Excerpts from an enlightening interview / conversation conducted by Brian Kennedy with Matt Kaeberlein on the biology of aging.
The interview took place in November 2020 as the first one under the healthy longevity webinar series organized by Brian Kennedy from the National University of Singapure (NUS).

During the conversation, Matt Kaeberlein makes a nice description about what aging is, as well as about therapies, drugs and other interventions that, at least in animals of various kinds, manage to modulate (delay / reverse) the progress of aging.

Among other projects, Matt Kaeberlein tells us that he’s planning to conduct an evaluation of various antiaging interventions in dogs.

To watch the entire interview, which has no waste, follow the link in the description of the video.

The interview took place in November 2020 as the first one under the healthy longevity webinar series organized by Dr. Brian Kennedy from the National University of Singapure (NUS).
During the conversation, Matt Kaeberlein makes a nice description about what aging is, as well as about therapies, drugs and other interventions that, at least in animals of various kinds, manage to modulate (delay / reverse) the progress of aging.

Among other projects, Pedro currently tells us that he is about to start an evaluation of various antiaging interventions in dogs.

To watch the entire interview, which has no waste, clic here: https://youtu.be/KhWHXU0GTOA

Read more | >

The human species has driven the planet’s biodiversity into an unprecedented decline, with as many as 1 million species at risk. Traditional conservation methods alone are struggling to offset the speed at which we’re losing species. Biotechnologies that have been developing in the wings are now being brought forward to potentially reverse the damage already done. Meet the scientist behind de-extinction.

#Moonshot #Science #BloombergQuicktake.
——-
Like this video? Subscribe: http://www.youtube.com/Bloomberg?sub_confirmation=1

QuickTake Originals is Bloomberg’s official premium video channel. We bring you insights and analysis from business, science, and technology experts who are shaping our future. We’re home to Hello World, Giant Leap, Storylines, and the series powering CityLab, Bloomberg Businessweek, Bloomberg Green, and much more.

Subscribe for business news, but not as you’ve known it: exclusive interviews, fascinating profiles, data-driven analysis, and the latest in tech innovation from around the world.

Visit our partner channel QuickTake News for breaking global news and insight in an instant.

Read more | >

Harvard’s Capasso Group has scaled up the achromatic metalens to 2mm in diameter. That may not sound like much, but it is plenty for virtual reality contact lenses. The human pupil is 7mm at widest. These guys are going to beat Mojo Lens to the finish line for smart contact lenses.

Read the latest updates on coronavirus from Harvard University. For SEAS specific-updates, please visit SEAS & FAS Division of Science: Coronavirus FAQs.

Read more | >

Research into a new drug that primes the immune system in the respiratory tract and is in development for COVID-19 shows it is also effective against rhinovirus.

Rhinovirus is the most common respiratory virus, the main cause of the common cold and is responsible for exacerbations of chronic respiratory diseases such as asthma and chronic obstructive pulmonary disease. In a study recently published in the European Respiratory Journal, the drug, known as INNA-X, is shown to be effective in a pre-clinical infection model and in human airway cells.

Treatment with INNA-X prior to infection with rhinovirus significantly reduced viral load and inhibited harmful inflammation.

Read more | >

When will the pandemic end? It’s the question hanging over just about everything since COVID-19 took over the world last year. The answer can be measured in vaccinations.

Bloomberg has built the biggest database of COVID-19 shots given around the world, with more than 108 million doses administered worldwide. U.S. science officials such as Anthony Fauci have suggested it will take 70% to 85% coverage of the population for things to return to normal. Bloomberg’s Vaccine Tracker shows that some countries are making far more rapid progress than others, using 75% coverage with a two-dose vaccine as a target.

Read more | >